AMRI appoints new vice president of aseptic services
AMRI has announced that Peter J. Hansbury, RPh, will assume leadership for the company's aseptic fill and finish facility located in Burlington, Massachusetts as vice president of aseptic services. He will report to Dr Steven Hagen, vice president of pharmaceutical development and manufacturing.
Peter J. Hansbury
Hansbury brings more than 30 years of technical, sales and leadership experience in sterile products for the pharmaceutical, biopharmaceutical and healthcare industries. Most recently, he served as vice president and general manager of contract manufacturing services for Boehringer-Ingelheim-Ben Venue Laboratories and was responsible for the overall management of Ben Venue's contract manufacturing services division. Prior to that, he held several roles of increasing responsibility during his 15-year career at Ben Venue, including director of marketing and customer operations of the Bedford Laboratories division of BenVenue Laboratories.
Prior to Ben Venue, he spent eight years at LyphoMed/Fujisawa USA in sales and operations positions culminating in the role of corporate marketing account executive. He has held additional leadership roles at The Cambridge Hospital, TPN Pharmacy and Massachusetts General Hospital with focus on management and supervision of pharmacy services.
Hansbury earned a BS in Pharmacy with honours at Northeastern University, College of Pharmacy and Allied Health, located in Boston, Massachusetts. He also holds licensure as a Registered Pharmacist from the Commonwealth of Massachusetts.
‘We are pleased to welcome Mr Hansbury to the AMRI leadership team,’ said vice president, pharmaceutical development and manufacturing Steven Hagen. ‘His expertise and experience in both the business of manufacturing and marketing speciality injectables and sterile products make him an excellent choice for this business realising an upswing in productivity and sales activity.’
‘We are excited to recruit Mr Hansbury into this leadership role for our sterile fill and finish facility,’ said chairman, ceo and president Dr Thomas E. D'Ambra. ‘We have been singularly focused on upgrades to systems and technology in pursuit of a full endorsement from the US FDA and Mr Hansbury joins us at a critical time as we resume GMP operations in Burlington.
‘We believe his diverse experience spanning operations, quality and sales and marketing will be an important contributor to the overall short and long term success of AMRI's Burlington operation.’
Subscribe now to Manufacturing Chemist to get unrestricted online access to our exclusive content and receive our high quality magazine every month.
|AMRI Albany Molecular Research||company profile|